Eli Lilly’s Zepbound injection pen has been approved by the FDA as the first drug treatment for patients with obesity and moderate-to-severe obstructive sleep apnea (OSA). The weekly injection, already known for weight loss, will enhance insurance coverage options. The approval highlights that a significant portion of the 80 million U.S. OSA patients are undiagnosed, with the drug showing promise in clinical trials—43% of non-PAP therapy patients and 51.5% of PAP therapy patients achieved resolution of OSA after one year. Zepbound aims to improve treatment options beyond traditional methods like CPAP machines.
